Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer
Status:
Completed
Trial end date:
2004-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop
cancer cells from growing. Drugs used in chemotherapy use different ways to stop tumor cells
from dividing so they stop growing or die. It is not yet known whether keyhole limpet
hemocyanin is more effective than doxorubicin for bladder cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of keyhole limpet hemocyanin
with that of doxorubicin in treating patients who have bladder cancer that has not responded
to BCG or in those patients who cannot tolerate BCG.